Saturday, April 07, 2007 10:54:23 AM
BioCryst Appoints Industry Veterans to Two Newly Created Positions, Vice President, Strategic Planning and Commercialization and Executive Director, Oncology Development
BIRMINGHAM, Ala., April 2 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced it has expanded its management team with the appointment of industry veterans to two newly created positions. As part of the company's goal to add scientific expertise and corporate leadership, David S. McCullough has been named Vice President, Strategic Planning and Commercialization, and Philip P. Breitfeld, M.D., has been named Executive Director, Oncology Development and Associate Chief Medical Officer.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030414/BIOCRYSTLOGO )
'As our lead products enter late-stage clinical testing, BioCryst is focusing on growing its pharmaceutical development expertise,' said Jon P. Stonehouse, Chief Executive Officer of BioCryst. 'The addition of these two highly respected, seasoned pharmaceutical professionals to our management team will be invaluable as we drive towards commercialization and continue the development of products in our pipeline.'
David McCullough most recently served as Director, Global Corporate Development in the Ethical Pharmaceuticals Division at Merck KGaA in Darmstadt, Germany. In that position he was responsible for leading the company's efforts in evaluating the commercial value of specific product opportunities and in the case of the Serono SA acquisition, their entire company portfolio. Mr. McCullough led the commercial assessment of strategic and financial attractiveness of over 40 companies in oncology and other therapeutic areas. Prior to that position, Mr. McCullough was an integral part of the Business Operations and Market Research Team in the Oncology Business Unit of Eli Lilly and Company. David started his career in healthcare as a sales representative at Zeneca Pharmaceuticals. With nearly 20 years of healthcare business experience, Mr. McCullough brings with him a background which includes extensive marketing, sales, general business management and international experience. In this new position, Mr. McCullough will be responsible for leading the development of and updating BioCryst's strategic plan and establishing global marketing strategies. In addition, Mr. McCullough will be responsible for executing the company's commercial plans beginning with Fodosine(TM) and Peramivir.
'As we begin initial planning for commercialization, David McCullough's expertise and business acumen will add significant strength to our executive management team,' said Mr. Stonehouse. 'David brings a wealth of experience in life sciences business analysis, product marketing and pharmaceutical sales that will be essential elements of our success as we continue to advance our pipeline and key product candidates including Fodosine(TM) in oncology, peramivir in seasonal and life-threatening influenza and BCX-4208 in autoimmune diseases and transplantation.'
Mr. McCullough received his Bachelor of Science degree from Western Illinois University.
Prior to joining BioCryst, Dr. Breitfeld was Medical Director, Oncology at EMD Pharmaceuticals, Inc. a U.S. based, wholly owned subsidiary of Merck KGaA of Darmstadt, Germany. In that position Dr. Breitfeld's responsibilities included the clinical development strategy for global product teams, and the evaluation of the clinical potential of product opportunities. As a pediatric oncologist, Dr. Breitfeld has been a member of and has held scientific leadership positions in the Children's Oncology Group. He was a widely respected academician during a 20-year academic career and has had previous appointments at Duke University, Indiana University, the University of Massachusetts, and Harvard University.
'We are extremely pleased to have Phil Breitfeld join BioCryst and our Clinical Development Group. He has extensive experience in the treatment of patients with a variety of hematologic and oncologic diseases, and throughout his career has been intimately involved in the design of clinical investigations of therapies for these conditions,' said W. James Alexander, M.D., M.P.H., Senior Vice President, Clinical and Regulatory Operations and Chief Medical Officer. 'The BioCryst product pipeline provides many opportunities for Phil to make significant contributions to our development programs.'
Dr. Breitfeld received his A.B. in Chemistry from Princeton University and his M.D. from the University of Rochester, School of Medicine.
About BioCryst
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine(TM) in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.
Regulatory
Send stock manipulators to: enforcement@sec.gov-and to jail.
Recent BCRX News
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 10/03/2024 11:00:53 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 11:06:38 AM
- BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome • GlobeNewswire Inc. • 10/02/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 11:11:26 AM
- U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile • GlobeNewswire Inc. • 09/30/2024 11:00:00 AM
- BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks • GlobeNewswire Inc. • 09/17/2024 11:00:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 09/10/2024 04:09:00 PM
- BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium • GlobeNewswire Inc. • 09/06/2024 06:00:11 AM
- BioCryst Appoints Dr. Donald Fong Chief Medical Officer • GlobeNewswire Inc. • 09/05/2024 11:00:00 AM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 09/04/2024 11:00:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:17:53 PM
- BioCryst to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 08/22/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/06/2024 08:38:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:05:05 AM
- BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/05/2024 11:00:24 AM
- U.S. Index Futures and Oil Prices Plunge on Recession Concerns • IH Market News • 08/05/2024 09:46:20 AM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/02/2024 11:00:47 AM
- BioCryst to Report Second Quarter 2024 Financial Results on August 5 • GlobeNewswire Inc. • 07/22/2024 11:00:09 AM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/02/2024 11:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 08:31:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 08:14:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:33:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:31:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:30:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:28:46 PM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM